Home  |  Site Map  |  Contact Us  |  
Search

 

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or relapsing forms of Multiple Sclerosis. REGNITE® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort recently granted exclusive world-wide rights for the development and commercialization of its clinical-stage oral product candidate, arbaclofen placarbil, to Reckitt Benckiser Pharmaceuticals, Inc. for all indications. XenoPort's pipeline of product candidates also includes a potential treatment for patients with Parkinson's disease.

For more information, please click here


For more information, please click here

Mon, 27 Jul 2015
XenoPort to Release Second Quarter Financial Results on August 5, 2015

Thu, 25 Jun 2015
XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use Disorder

 

Q2 2015 XenoPort, Inc. Earnings Conference Call
August 5, 2015 at 5:00 PM ET

Jefferies 2015 Global Healthcare Conference
Jun 4, 2015 7:00 AM PT

XenoPort is focused on development of product candidates for the potential treatment of central nervous system (CNS) disorders, including spasticity, Parkinsonís disease and relapsing-remitting multiple sclerosis.

Explore the XenoPort Pipeline >